Key takeaways for South Dakota
- • Zepbound is the FIRST and ONLY FDA-approved drug for OSA (Dec 2024).
- • Approved only for moderate-to-severe OSA in adults with obesity.
- • AHI reductions of 25-30 events/hour in the SURMOUNT-OSA trials.
- • South Dakota Medicaid coverage rules apply for Obstructive Sleep Apnea patients in South Dakota — see Medicaid section below.
- • 16 GLP-1 telehealth providers available nationwide.
Why GLP-1 medications for Obstructive Sleep Apnea
Zepbound is FDA-approved (Dec 2024) for moderate-to-severe obstructive sleep apnea in adults with obesity. Evidence grade: A. In the SURMOUNT-OSA trials, tirzepatide reduced the apnea-hypopnea index (AHI) by roughly 25-30 events per hour at 52 weeks, with a substantial fraction of patients reaching disease remission. CPAP remains standard of care — Zepbound is positioned as adjunct or alternative for patients who cannot tolerate CPAP. Other GLP-1s (Wegovy, semaglutide) are not approved for OSA but may produce indirect benefit via weight loss.
South Dakota-specific context
South Dakota has telehealth access concentrated in Sioux Falls, Rapid City, Aberdeen metros, with additional reach to Brookings and Watertown. Sanford Health, Avera Health is the largest in-state academic medical center for endocrine + obesity-medicine specialty consults. The state health authority publishes prescribing + coverage updates at doh.sd.gov.
South Dakotatelehealth & pricing rules
- • South Dakota permits audio-only and asynchronous telehealth visits for GLP-1 care.
- • South Dakota allows new-patient telehealth prescribing without a prior in-person visit.
- • Typical cash GLP-1 price in South Dakota: ~$232/mo (compounded options often lower, brand higher).
State telehealth statutes change — verify current rules with your provider before booking.